Makrogol is commonly used to address constipation (difficulty pooing) and can also be applied to help clear a build-up of hard stool in the bowel, a condition known as faecal impaction.

---

Long-Term Support for Chronic Constipation

Makrogol is generally used for the extended management of chronic constipation, a condition characterized by periods of heightened symptoms such as infrequent or difficult bowel movements. The medication contributes to improved or more regular bowel function, offering durable support to ease the overall symptomatic burden over time. Its therapeutic domains include addressing symptoms of hard stools, straining, and the sensation of incomplete evacuation.

“The primary goal is to provide supportive relief that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.”

---

Applied in Addressing Severe Faecal Impaction

In more acute clinical settings, Makrogol is commonly used to address faecal impaction, a condition marked by increased physiological stress due to the accumulation of retained stool. This intervention may assist with achieving disimpaction, which supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort.

---

Quick Fact: Relief for Difficulty and Discomfort Makrogol assists in easing the physical effort during defecation and is relevant when symptoms create noticeable physiological strain.

Official Eligibility and Contraindications

The eligibility profile for Macrogol (Polyethylene Glycol) is strictly defined by regulatory documents, focusing on patient safety based on underlying health status and age.

Macrogol is officially contraindicated in patients with:

• Known or suspected bowel obstruction (ileus).
• Gastrointestinal perforation or a high risk of perforation.
• Severe inflammatory conditions of the intestinal tract (such as Crohn’s disease or ulcerative colitis).
• Toxic megacolon or known hypersensitivity to polyethylene glycol.

Populations with Approved or Conditional Use:

Use is generally approved for adults and the elderly. Most regulatory labels permit use in adolescents (typically ge 12 years or ge 17 years, depending on the region). Use in children under 12 is typically not recommended for adult formulations, requiring physician determination.

Regarding life stage, use during pregnancy and lactation is generally permitted by regulatory bodies, as systemic exposure is considered negligible. For patients with kidney disease, some regulatory labels (US OTC) advise against use unless supervised by a physician.

Interactions with other medicines and products

Makrogol (Polyethylene Glycol or PEG) is an osmotic laxative that is not systemically absorbed, meaning its interaction profile is dominated by effects within the gastrointestinal tract, rather than metabolic enzyme pathways.

Documented Interaction Mechanisms

The primary interaction pattern is a pharmacokinetic interaction leading to the reduced systemic absorption of co-administered oral medications. This occurs because Makrogol accelerates the speed of intestinal transit. To address this officially documented effect, regulatory labels mandate that other oral medicinal products must be separated from Makrogol administration by at least one hour.

Another significant pattern is the pharmacodynamic interaction, which creates an additive risk of certain adverse effects when combined with specific drug classes.

Interaction-Related Restrictions

Classification	Interacting Substance/Class	Official Restriction
Additive Risk	Stimulant Laxatives (e.g., Bisacodyl, Senna)	Co-administration is strongly advised against due to an increased risk of colonic mucosal injury.
Additive Risk	Medications affecting fluid and electrolyte levels (Diuretics, ACE Inhibitors, NSAIDs)	Increased risk of fluid and electrolyte abnormalities; specific caution is required for patients with Renal Impairment.
Product Compatibility	Starch-based thickeners	Official guidance advises against adding these thickeners to the prepared solution.

Makrogol is not documented in official prescribing information as having interactions with the Cytochrome P450 (CYP) enzyme system or drug transporters.

Osmotic Action and Intraluminal Fluid Dynamics

Makrogol (Polyethylene Glycol) is a biologically inert osmotic agent that operates exclusively within the gastrointestinal (GI) lumen. It functions as a hydrophilic molecule, targeting and binding to water via hydrogen bonding within the bowel. This action establishes a high-solute gradient, driving the movement of water from the body’s interstitial space across the intestinal barrier into the colon lumen via osmosis. This physicochemical mechanism directly targets the fluid content of the bowel, resulting in a hydrated and softened fecal mass.

---

Bulk Expansion and Peripheral Motility Modulation

The resulting increase in fluid volume leads to substantial bulk expansion and subsequent distension of the colonic wall. This physical distension serves as the physiological trigger for the bowel’s stretch reflex, mechanically stimulating peristaltic contractions via the enteric nervous system. This peripheral mechanism of action promotes the propulsion and subsequent evacuation of the hydrated stool through the colon.

How to Use Makrogol

Macrogol (Polyethylene Glycol 3350) is administered exclusively through the oral route, after reconstitution. The standard dosage form is a powder for oral solution, which must be fully dissolved in a specified volume of water or other beverage prior to consumption.

---

Official Administration Guidelines

The usage protocol is defined by the specific clinical need and formulation, establishing limits for dose, frequency, and duration.

Parameter	Standard Instructions
Dosing for Chronic Constipation	The starting dose is typically one sachet daily (e.g., 13.125 g or 17 g), which can be adjusted to a range of 1 to 3 sachets daily in divided doses, based on individual response.
Dosing for Faecal Impaction	A higher regimen of 8 sachets daily (13.125 g strength) is used. The total daily dose must be consumed over a 6-hour period.
Course Duration	The standard treatment course is generally time-limited, typically not exceeding two weeks for chronic constipation and three days for faecal impaction, with any extension requiring professional supervision.

---

Preparation and Procedural Constraints

To ensure proper function, Macrogol powder must be dissolved. For the standard sachet, this typically requires dilution in 125 mL of water. The solution can be taken with or without food. For patients with impaired cardiovascular function receiving faecal impaction treatment, consumption is restricted to no more than two sachets in any one hour, reflecting specific procedural constraints. The total daily dose may be divided and administered at various times throughout the day, except when a regimen is specifically time-bound, such as for impaction.

Makrogol: Recent Clinical Evidence

Research Summary

Makrogol, a high-molecular-weight polyethylene glycol (PEG) polymer, is used in the treatment of functional constipation in both adult and pediatric populations. Research suggests that it acts primarily as an osmotic laxative, drawing water into the intestinal lumen. This process is thought to increase the water content and volume of stool, which may facilitate colonic transit and make bowel movements easier to pass.

Key Clinical Findings

Clinical trials, including randomized controlled trials (RCTs), have evaluated makrogol’s effect on constipation-related symptoms. Key findings reported by research include the following:

• Symptom Relief: Studies have consistently reported that treatment with makrogol is associated with improvements in both stool frequency and stool consistency compared to placebo.
• Comparisons: Evidence from systematic reviews indicates that makrogol preparations show clinical benefit that is at least comparable to, and in some comparative trials, greater than, that of other common osmotic agents like lactulose in both children and adults.

Tolerability and Long-Term Use

Makrogol is generally considered well-tolerated across various patient groups.

Outcome Examined	Trial Findings
Adverse Events	Common reported side effects are generally mild and gastrointestinal, such as abdominal pain, bloating, and nausea.
Electrolyte Balance	When administered without electrolytes, clinical trials have indicated that makrogol use does not appear to cause clinically relevant electrolyte imbalances in most patient populations.
Long-Term Profile	Studies examining use for up to 12 months in patients with chronic constipation, including the elderly, found that the therapeutic responses tended to be durable without an increase in dosage.

Research Caution

It is important to note that the information presented here summarizes research outcomes and is not a substitute for professional medical guidance. Patients should discuss their individual clinical needs and suitability for treatment with a healthcare provider.

Key Studies & References

1. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use

Common questions about Makrogol (FAQ)

Q: What is Makrogol and how does it work?

A: Makrogol, also known as polyethylene glycol (PEG), is a type of medicine used primarily to treat constipation. It belongs to a class of medicines called osmotic laxatives.

Makrogol works by drawing water into the bowels (intestines). This water softens the stool and increases its volume, making it easier to pass. It is generally not absorbed into the body, meaning it acts locally within the digestive tract.

Q: What is the main use of Makrogol?

A: The main use of Makrogol is to treat chronic constipation in adults and children. It can also be used to clear the bowels before medical procedures, such as a colonoscopy, though specific formulations for this use often contain electrolytes in addition to Makrogol.

Q: How long does it take for Makrogol to work?

A: Makrogol generally begins to work within 1 to 3 days of starting treatment. It is not a fast-acting laxative for immediate relief and should be taken as part of a regular treatment plan for constipation. For the preparation of a colonoscopy, the effect is much faster due to the high dosage taken over a short period.

Q: Can children take Makrogol?

A: Yes, Makrogol is commonly used to treat constipation in children. The appropriate dose will depend on the child's age, weight, and the severity of their constipation. A healthcare provider should be consulted to determine the correct formulation and dosage for a child.

Q: What are the common side effects of Makrogol?

A: Common side effects are generally mild and related to the drug's action in the gut. They may include:

• Abdominal pain or discomfort
• Bloating
• Nausea
• Diarrhea (usually a sign of too high a dose)

These side effects often decrease as the body adjusts to the medication or if the dose is lowered.

Q: Should Makrogol be taken with food?

A: Makrogol can be taken with or without food. It is typically dissolved in a glass of water or another beverage (like juice or tea) before consumption. Following the specific instructions provided with your particular Makrogol product is important.

Q: Are there any drugs that should not be taken with Makrogol?

A: Makrogol is generally considered safe with few drug interactions. However, because it speeds up the transit time of contents through the gut, it might potentially reduce the absorption of other orally administered medicines taken at the same time. To avoid this, it is often recommended to take other oral medications at least 1 hour before or 2 hours after taking Makrogol, unless a doctor or pharmacist advises otherwise.

Q: What should I do if I miss a dose?

A: If you miss a dose of Makrogol, simply take the next dose at the regular time. Do not take a double dose to make up for a missed one. Consistent, daily use as prescribed is key for treating chronic constipation.

Q: Is Makrogol addictive or habit-forming?

A: Makrogol is generally not considered addictive or habit-forming like some other types of laxatives. It works by a simple physical mechanism (osmosis) and does not typically lead to the gut becoming dependent on the medicine for function. It can often be used long-term under medical supervision.

The storage and disposal of Makrogol (Polyethylene Glycol 3350) are governed by official regulatory requirements.

Storage Conditions	Details (Mandatory Requirements)
Powder Temperature	Store at Controlled Room Temperature (20^circC to 25^circC). Protect from freezing, excess heat, and moisture [Source: FDA, EMA].
Container & Protection	Keep the medicine in its original container and ensure the cap is tightly closed. Store out of the sight and reach of children [Source: NIH MedlinePlus].
Solution Stability	The reconstituted oral solution must be stored refrigerated (2^circC to 8^circC) and must be discarded after 24 hours [Source: EMA SmPC].

Official Disposal Instructions

Unused or expired Makrogol should be disposed of primarily through an authorized drug take-back program [Source: FDA]. If this is unavailable, the powder must be removed from its container, mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed bag, and then thrown into the household trash. Disposal must always adhere to local requirements.